Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naldemedine plus tramadol for prevention of opioid-induced constipation in non-cancer chronic pain
jRCTs031240565Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of naldemedine and tramadol in chronic pain and opioid-induced constipation (OIC), sponsored by Shionogi & Co., Ltd. Primary endpoint: Incidence of opioid-induced constipation during 14-day observation. Started Jan 2025; status: completed.
02
Drugs
naldemedinetramadol
03
Conditions
chronic painopioid-induced constipation (OIC)
Beyond the preview
Go deeper on jRCTs031240565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240565.